Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/106804
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baldeiras, Inês | - |
dc.contributor.author | Santana, Isabel | - |
dc.contributor.author | Leitão, Maria João | - |
dc.contributor.author | Vieira, Daniela | - |
dc.contributor.author | Duro, Diana | - |
dc.contributor.author | Mroczko, Barbara | - |
dc.contributor.author | Kornhuber, Johannes | - |
dc.contributor.author | Lewczuk, Piotr | - |
dc.date.accessioned | 2023-04-24T09:03:11Z | - |
dc.date.available | 2023-04-24T09:03:11Z | - |
dc.date.issued | 2019-01-05 | - |
dc.identifier.issn | 1758-9193 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/106804 | - |
dc.description.abstract | Background: The previously described and validated Erlangen Score (ES) algorithm enables interpretation of the cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), ordering them on an ordinal scale: from neurochemically normal (ES = 0) through improbable AD (ES = 1), possible AD (ES = 2 or 3), to probable AD (ES = 4). Here we assess the accuracy of the ES in predicting hazards of progression from the mild cognitive impairment (MCI) stage of AD to the dementia stage of the disease (Alzheimer’s disease dementia (ADD)) in a novel, single-center cohort. Methods: Baseline CSF biomarkers (amyloid beta (Aβ) 1–42, Aβ42/40, Tau, and pTau181), interpreted according to the ES, were used to estimate time to progression from the MCI stage of AD to ADD, conditional on age, gender, APOE ε4 genotype, and Mini Mental State Examination score in 144 MCI subjects, using the Extended Cox Model; the subjects were followed-up until they developed dementia or until they had been cognitively stable for at least 2 years. In addition, ES distributions were studied in 168 ADD cases and 66 neurologic controls. Further, we stratified MCI patients into those who progressed to ADD faster (within 3 years, n = 47) and those who progressed slower (n = 74). Results: The distributions of the ES categories across the four diagnostic groups (Controls, MCI-Stable, MCI-AD, and ADD) were highly significantly different (Kruskal–Wallis χ2(df = 3) = 151.4, p < 0.001), with significant contrasts between each pair (p < 0.005), except between the ADD and the MCI-AD groups (p = 1.0). MCI patients with ES = 2 or 3 had 6–8 times higher hazards to progress to ADD compared to patients with ES = 0 or 1 in the first 3 follow-up years, and then their hazards decreased to those of the group with ES = 0 or 1. Patients with ES = 4 had hazards 8–12 times higher compared to the ES = 0 or 1 group. Faster progressors with ES = 2 or 3 had, in comparison to slower progressors, significantly lower Aβ1–42, Aβ1–40, and Aβ42/40, but comparable Tau and pTau181. A highly significant difference of the ES distributions between these two groups was observed (p < 0.001). Conclusions: Our current results reconfirm and extend the conclusions of the previously published report that the Erlangen Score is a useful tool facilitating interpretation of a complex pattern of the CSF AD biomarkers. | pt |
dc.description.sponsorship | The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n° 115372, the resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution. This work was also financed by the European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme under project CENTRO-01- 0145-FEDER-000008:BrainHealth 2020, and through the COMPETE 2020—- Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT—Fundação para a Ciência e a Tecnologia, I.P., under project POCI-01-0145-FEDER-007440. MJL and DD were supported by the Portuguese Foundation for Science and Technology (refs PD/BD/ 135108/2017 and SFRH/BD/52289/2013, respectively). | pt |
dc.language.iso | eng | pt |
dc.publisher | Springer Nature | pt |
dc.relation | PD/BD/135108/2017 | pt |
dc.relation | SFRH/BD/52289/2013 | pt |
dc.relation | CENTRO-01- 0145-FEDER-000008:BrainHealth 2020 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | Alzheimer’s disease | pt |
dc.subject | Mild cognitive impairment—progression | pt |
dc.subject | Cerebrospinal fluid | pt |
dc.subject | Biomarker | pt |
dc.subject.mesh | Aged | pt |
dc.subject.mesh | Alzheimer Disease | pt |
dc.subject.mesh | Amyloid beta-Peptides | pt |
dc.subject.mesh | Biomarkers | pt |
dc.subject.mesh | Cognitive Dysfunction | pt |
dc.subject.mesh | Cohort Studies | pt |
dc.subject.mesh | Female | pt |
dc.subject.mesh | Follow-Up Studies | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Male | pt |
dc.subject.mesh | Mental Status and Dementia Tests | pt |
dc.subject.mesh | Middle Aged | pt |
dc.subject.mesh | Predictive Value of Tests | pt |
dc.subject.mesh | tau Proteins | pt |
dc.subject.mesh | Algorithms | pt |
dc.subject.mesh | Disease Progression | pt |
dc.title | Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease | pt |
dc.type | article | - |
degois.publication.firstPage | 2 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Alzheimer's Research and Therapy | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1186/s13195-018-0456-x | pt |
degois.publication.volume | 11 | pt |
dc.date.embargo | 2019-01-05 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-8106-7308 | - |
crisitem.author.orcid | 0000-0002-8114-9434 | - |
crisitem.author.orcid | 0000-0002-8950-1439 | - |
Appears in Collections: | I&D CNC - Artigos em Revistas Internacionais FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Erlangen-Score-as-a-tool-to-predict-progression-from-mild-cognitive-impairment-to-dementia-in-Alzheimers-diseaseAlzheimers-Research-and-Therapy.pdf | 776.11 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
20
checked on Sep 2, 2024
WEB OF SCIENCETM
Citations
16
checked on Jul 2, 2024
Page view(s)
95
checked on Oct 16, 2024
Download(s)
96
checked on Oct 16, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License